TY  - JOUR
A1  - Wendler, Petra
A1  - Enenkel, Cordula
T1  - Nuclear Transport of Yeast Proteasomes
JF  - Frontiers in molecular biosciences
N2  - Proteasomes are key proteases in regulating protein homeostasis. Their holo-enzymes are composed of 40 different subunits which are arranged in a proteolytic core (CP) flanked by one to two regulatory particles (RP). Proteasomal proteolysis is essential for the degradation of proteins which control time-sensitive processes like cell cycle progression and stress response. In dividing yeast and human cells, proteasomes are primarily nuclear suggesting that proteasomal proteolysis is mainly required in the nucleus during cell proliferation. In yeast, which have a closed mitosis, proteasomes are imported into the nucleus as immature precursors via the classical import pathway. During quiescence, the reversible absence of proliferation induced by nutrient depletion or growth factor deprivation, proteasomes move from the nucleus into the cytoplasm. In the cytoplasm of quiescent yeast, proteasomes are dissociated into CP and RP and stored in membrane-less cytoplasmic foci, named proteasome storage granules (PSGs). With the resumption of growth, PSGs clear and mature proteasomes are transported into the nucleus by Blm10, a conserved 240 kDa protein and proteasome-intrinsic import receptor. How proteasomes are exported from the nucleus into the cytoplasm is unknown.
KW  - proteasome
KW  - nuclear transport
KW  - importin
KW  - karyopherin
KW  - Blm10
KW  - proteasome storage granules
Y1  - 2019
U6  - https://doi.org/10.3389/fmolb.2019.00034
SN  - 2296-889X
VL  - 6
PB  - Frontiers Research Foundation
CY  - Lausanne
ER  - 
TY  - GEN
A1  - Schieferdecker, Anne
A1  - Wendler, Petra
T1  - Structural mapping of missense mutations in the Pex1/Pex6 complex
T2  - Postprints der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe
N2  - Peroxisome biogenesis disorders (PBDs) are nontreatable hereditary diseases with a broad range of severity. Approximately 65% of patients are affected by mutations in the peroxins Pex1 and Pex6. The proteins form the heteromeric Pex1/Pex6 complex, which is important for protein import into peroxisomes. To date, no structural data are available for this AAA+ ATPase complex. However, a wealth of information can be transferred from low-resolution structures of the yeast scPex1/scPex6 complex and homologous, well-characterized AAA+ ATPases. We review the abundant records of missense mutations described in PBD patients with the aim to classify and rationalize them by mapping them onto a homology model of the human Pex1/Pex6 complex. Several mutations concern functionally conserved residues that are implied in ATP hydrolysis and substrate processing. Contrary to fold destabilizing mutations, patients suffering from function-impairing mutations may not benefit from stabilizing agents, which have been reported as potential therapeutics for PBD patients.
T3  - Zweitveröffentlichungen der Universität Potsdam : Mathematisch-Naturwissenschaftliche Reihe - 1072 
KW  - Zellweger syndrome spectrum disorder (ZSSD)
KW  - Zellweger
KW  - structure
KW  - Pex1
KW  - Pex6
KW  - mutation
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:517-opus4-472843
SN  - 1866-8372
IS  - 1072
ER  - 
TY  - JOUR
A1  - Schieferdecker, Anne
A1  - Wendler, Petra
T1  - Structural Mapping of Missense Mutations in the Pex1/Pex6 Complex
JF  - International journal of molecular sciences
N2  - Peroxisome biogenesis disorders (PBDs) are nontreatable hereditary diseases with a broad range of severity. Approximately 65% of patients are affected by mutations in the peroxins Pex1 and Pex6. The proteins form the heteromeric Pex1/Pex6 complex, which is important for protein import into peroxisomes. To date, no structural data are available for this AAA+ ATPase complex. However, a wealth of information can be transferred from low-resolution structures of the yeast scPex1/scPex6 complex and homologous, well-characterized AAA+ ATPases. We review the abundant records of missense mutations described in PBD patients with the aim to classify and rationalize them by mapping them onto a homology model of the human Pex1/Pex6 complex. Several mutations concern functionally conserved residues that are implied in ATP hydrolysis and substrate processing. Contrary to fold destabilizing mutations, patients suffering from function-impairing mutations may not benefit from stabilizing agents, which have been reported as potential therapeutics for PBD patients.
KW  - Zellweger syndrome spectrum disorder (ZSSD)
KW  - Zellweger
KW  - structure
KW  - Pex1
KW  - Pex6
KW  - mutation
Y1  - 2019
U6  - https://doi.org/10.3390/ijms20153756
SN  - 1422-0067
VL  - 20
IS  - 15
PB  - MDPI
CY  - Basel
ER  -